2025 Q4 -tulosraportti
Vain PDF
43 päivää sitten
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 000 | - | - | ||
| 6 000 | - | - | ||
| 1 000 | - | - | ||
| 2 000 | - | - | ||
| 1 284 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·2 t sitten🧬 "HOW HIGH WILL WE GO?" — MANY ASK 🧬 And no one has the definitive answer. Biotech in general, and stocks like Circio rarely go straight up without fluctuations along the way. And there will probably be more red days, where people secure profits, become uncertain, "sell the news", who trade the stock. That is completely normal. But what makes Circio exciting now is that the company suddenly starts delivering on several fronts simultaneously: - strong data - great international attention - patent applications - several collaborations, including research collaboration with AaviGen. - increasing interest around circVec It is precisely such periods that often build the foundation for further upside! The market still seems to be trying to understand how big circVec can actually become. I'm holding on 🚂 (PS: Not financial advice. Do your own research and make your own choices.)
5 t sitten5 t sittenDe-Risking Circio: 8 Biological Proofs That circVec Solves the "Mouse-to-Human" Gap In biotech, the biggest risk to our capital is the notorious "Mouse-to-Human" gap. Over 80% of traditional drugs fail in Phase 1/2 clinical trials because human biology rejects what worked perfectly in a lab rat. Circio’s proprietary circular RNA platform, circVec, fundamentally changes this risk profile. Ahead of this Friday’s (May 29) highly anticipated PhD defense at Karolinska Institutet (KI),which documents the precise cellular mechanisms of circular RNA-here are 8 biologically backed reasons why preclinical results for circVec are highly predictive of human clinical success: 1. Universal Biology & "Plug-and-Play" Production The Science: The cellular machinery that processes the circVec vector (ribosomes and spliceosomes) is universal across mammals. The Risk: RNA circularization and ribosome binding efficiency can theoretically vary between mouse and human cells. The Proof (Risk Mitigated): The KI research tested directly on human primary cells, confirming that human cellular machinery perfectly translates circular RNA structures. Furthermore, Circio has continually optimized novel genetic elements (such as those in circVec Gen 4.0) that dramatically improve intracellular circularization efficiency, ensuring maximum, predictable protein output regardless of the host species. 2. Bypassing the "Protein Pocket" Problem The Science: circVec delivers a genetic "software update" to manufacture the human protein directly inside the cell, completely bypassing the structural differences between mouse and human cell receptors that cause chemical drugs to fail. The Risk: Lab mice usually have temporary, "induced" conditions that don't mimic decades of complex human disease progression. The Proof (Risk Mitigated): The KI thesis validated the circRNA mechanism directly on tissues taken from actual patients with chronic, long-standing diabetic ulcers. This proves the technology functions optimally even in a degraded, real-world human disease environment. 3. Extreme and Predictable Stability The Science: The closed, circular structure of circVec-generated RNA evades exonucleases (cellular enzymes that quickly eat standard linear mRNA from the ends). The Risk: Other enzymes (endonucleases) could still chop the RNA from the middle during high cellular stress. The Proof (Risk Mitigated): Circio’s in vivo data demonstrates that circVec achieves significantly extended durability and sustained therapeutic expression in mice compared to linear mRNA. The KI research validates that this superior structural stability holds true in humans, confirming prolonged therapeutic effects even within the highly stressed, oxidative environments of chronic human wounds. 4. Eliminating Unpredictable Liver Toxicity The Science: Unlike chemical drugs, circVec doesn't rely on unpredictable liver enzymes for clearance—a classic point of failure in Phase 1 trials. The Risk: Systemic gene therapies (delivered intravenously) often accumulate in the human liver, causing severe toxicity. The Proof (Risk Mitigated): The KI research proves that localized delivery of circRNA completely avoids systemic blood filtration and liver clearance. This aligns with Circio’s strategic expansion into local and non-viral delivery vectors (such as their partnership with TraffikGene for LNP delivery), allowing the therapy to reach target tissues without risking liver toxicity. 5. Immune "Stealth" and Dramatic Dose Reduction The Science: Standard mRNA often triggers inflammatory alarms because its exposed ends are recognized by the body as viral threats. circVec lacks these ends, allowing it to hide from the innate immune system. The Risk: The viral AAV vector delivering the RNA can still trigger dangerous immune responses if administered in high doses. The Proof (Risk Mitigated): Because circVec generates up to 40-fold higher protein expression than standard mRNA-AAVs, Circio's data confirms that clinical doses can be drastically reduced. Combining significantly lower vector doses with the intracellular "stealth" of circular RNA massively de-risks the threat of trial-killing immune reactions. 6. Exploitation of Universal Repair Cells The Science: Connective tissue cells (fibroblasts) operate identically across all mammals. The Risk: Mice heal wounds by contracting a skin muscle; humans must slowly rebuild tissue from scratch. The Proof (Risk Mitigated): KI researchers used "splinted" models that physically locked the mouse's anatomy, forcing them to heal exactly like humans. The results proved that the fundamental mechanism of circular RNA successfully drives true, human-style tissue regeneration.
·5 t sittenI see that Geara defended a PhD in April 2026 but what happens on May 29??? AI???·4 t sittenJennifer Geara defends her doctoral degree this Friday, May 29, and not in April.
·7 t sitten...even more attention on LinkedIn, https://www.linkedin.com/posts/pharmanews-biotech-genetherapy-share-7465465764813328385-cq-e/?utm_source=share&utm_medium=member_ios&rcm=ACoAABfsrdgBOH7SNLgjuj2ThRvG2-zvaDmJLOEhttps://www.linkedin.com/posts/martin-busch-186197185_genetherapy-aav-circularrna-share-7465475593606905856-4FZO/?utm_source=share&utm_medium=member_ios&rcm=ACoAABfsrdgBOH7SNLgjuj2ThRvG2-zvaDmJLOE·7 t sitten · MuokattuJust here in the small pond around Oslo S and in West Oslo, they still haven't understood what the company is about to create.🔥 Neither FA, DN nor E24 manage to grasp this. They are going to get a punch in the face when the company is soon bought. It won't be long now. Big Pharma doesn't wait. Now we see Lilly buying pre-clinical every day for 15 mrd. 🔥
·7 t sittenThanks — it hits a good middle ground that is often missing in such discussions. You acknowledge both the upside and the risk without ending up in either blind hype or excessive pessimism. Especially the fact that the price remains relatively high after a strong rise is an interesting signal in itself. In many speculative cases, one often sees a full retrace quite quickly when profit-taking begins. That the market still prices Circio around these levels could indicate that more people are actually trying to assess the technology more seriously now. At the same time, you are clear about the most important things: * no one knows the outcome, * biotech is extremely binary, * and the risk is still high. This makes the text more credible than many posts that portray early-stage biotech as almost "guaranteed success".
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
43 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sitten🧬 "HOW HIGH WILL WE GO?" — MANY ASK 🧬 And no one has the definitive answer. Biotech in general, and stocks like Circio rarely go straight up without fluctuations along the way. And there will probably be more red days, where people secure profits, become uncertain, "sell the news", who trade the stock. That is completely normal. But what makes Circio exciting now is that the company suddenly starts delivering on several fronts simultaneously: - strong data - great international attention - patent applications - several collaborations, including research collaboration with AaviGen. - increasing interest around circVec It is precisely such periods that often build the foundation for further upside! The market still seems to be trying to understand how big circVec can actually become. I'm holding on 🚂 (PS: Not financial advice. Do your own research and make your own choices.)
- 5 t sitten5 t sittenDe-Risking Circio: 8 Biological Proofs That circVec Solves the "Mouse-to-Human" Gap In biotech, the biggest risk to our capital is the notorious "Mouse-to-Human" gap. Over 80% of traditional drugs fail in Phase 1/2 clinical trials because human biology rejects what worked perfectly in a lab rat. Circio’s proprietary circular RNA platform, circVec, fundamentally changes this risk profile. Ahead of this Friday’s (May 29) highly anticipated PhD defense at Karolinska Institutet (KI),which documents the precise cellular mechanisms of circular RNA-here are 8 biologically backed reasons why preclinical results for circVec are highly predictive of human clinical success: 1. Universal Biology & "Plug-and-Play" Production The Science: The cellular machinery that processes the circVec vector (ribosomes and spliceosomes) is universal across mammals. The Risk: RNA circularization and ribosome binding efficiency can theoretically vary between mouse and human cells. The Proof (Risk Mitigated): The KI research tested directly on human primary cells, confirming that human cellular machinery perfectly translates circular RNA structures. Furthermore, Circio has continually optimized novel genetic elements (such as those in circVec Gen 4.0) that dramatically improve intracellular circularization efficiency, ensuring maximum, predictable protein output regardless of the host species. 2. Bypassing the "Protein Pocket" Problem The Science: circVec delivers a genetic "software update" to manufacture the human protein directly inside the cell, completely bypassing the structural differences between mouse and human cell receptors that cause chemical drugs to fail. The Risk: Lab mice usually have temporary, "induced" conditions that don't mimic decades of complex human disease progression. The Proof (Risk Mitigated): The KI thesis validated the circRNA mechanism directly on tissues taken from actual patients with chronic, long-standing diabetic ulcers. This proves the technology functions optimally even in a degraded, real-world human disease environment. 3. Extreme and Predictable Stability The Science: The closed, circular structure of circVec-generated RNA evades exonucleases (cellular enzymes that quickly eat standard linear mRNA from the ends). The Risk: Other enzymes (endonucleases) could still chop the RNA from the middle during high cellular stress. The Proof (Risk Mitigated): Circio’s in vivo data demonstrates that circVec achieves significantly extended durability and sustained therapeutic expression in mice compared to linear mRNA. The KI research validates that this superior structural stability holds true in humans, confirming prolonged therapeutic effects even within the highly stressed, oxidative environments of chronic human wounds. 4. Eliminating Unpredictable Liver Toxicity The Science: Unlike chemical drugs, circVec doesn't rely on unpredictable liver enzymes for clearance—a classic point of failure in Phase 1 trials. The Risk: Systemic gene therapies (delivered intravenously) often accumulate in the human liver, causing severe toxicity. The Proof (Risk Mitigated): The KI research proves that localized delivery of circRNA completely avoids systemic blood filtration and liver clearance. This aligns with Circio’s strategic expansion into local and non-viral delivery vectors (such as their partnership with TraffikGene for LNP delivery), allowing the therapy to reach target tissues without risking liver toxicity. 5. Immune "Stealth" and Dramatic Dose Reduction The Science: Standard mRNA often triggers inflammatory alarms because its exposed ends are recognized by the body as viral threats. circVec lacks these ends, allowing it to hide from the innate immune system. The Risk: The viral AAV vector delivering the RNA can still trigger dangerous immune responses if administered in high doses. The Proof (Risk Mitigated): Because circVec generates up to 40-fold higher protein expression than standard mRNA-AAVs, Circio's data confirms that clinical doses can be drastically reduced. Combining significantly lower vector doses with the intracellular "stealth" of circular RNA massively de-risks the threat of trial-killing immune reactions. 6. Exploitation of Universal Repair Cells The Science: Connective tissue cells (fibroblasts) operate identically across all mammals. The Risk: Mice heal wounds by contracting a skin muscle; humans must slowly rebuild tissue from scratch. The Proof (Risk Mitigated): KI researchers used "splinted" models that physically locked the mouse's anatomy, forcing them to heal exactly like humans. The results proved that the fundamental mechanism of circular RNA successfully drives true, human-style tissue regeneration.·5 t sittenI see that Geara defended a PhD in April 2026 but what happens on May 29??? AI???·4 t sittenJennifer Geara defends her doctoral degree this Friday, May 29, and not in April.
- ·7 t sitten...even more attention on LinkedIn, https://www.linkedin.com/posts/pharmanews-biotech-genetherapy-share-7465465764813328385-cq-e/?utm_source=share&utm_medium=member_ios&rcm=ACoAABfsrdgBOH7SNLgjuj2ThRvG2-zvaDmJLOEhttps://www.linkedin.com/posts/martin-busch-186197185_genetherapy-aav-circularrna-share-7465475593606905856-4FZO/?utm_source=share&utm_medium=member_ios&rcm=ACoAABfsrdgBOH7SNLgjuj2ThRvG2-zvaDmJLOE·7 t sitten · MuokattuJust here in the small pond around Oslo S and in West Oslo, they still haven't understood what the company is about to create.🔥 Neither FA, DN nor E24 manage to grasp this. They are going to get a punch in the face when the company is soon bought. It won't be long now. Big Pharma doesn't wait. Now we see Lilly buying pre-clinical every day for 15 mrd. 🔥
- ·7 t sittenThanks — it hits a good middle ground that is often missing in such discussions. You acknowledge both the upside and the risk without ending up in either blind hype or excessive pessimism. Especially the fact that the price remains relatively high after a strong rise is an interesting signal in itself. In many speculative cases, one often sees a full retrace quite quickly when profit-taking begins. That the market still prices Circio around these levels could indicate that more people are actually trying to assess the technology more seriously now. At the same time, you are clear about the most important things: * no one knows the outcome, * biotech is extremely binary, * and the risk is still high. This makes the text more credible than many posts that portray early-stage biotech as almost "guaranteed success".
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 000 | - | - | ||
| 6 000 | - | - | ||
| 1 000 | - | - | ||
| 2 000 | - | - | ||
| 1 284 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
43 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sitten🧬 "HOW HIGH WILL WE GO?" — MANY ASK 🧬 And no one has the definitive answer. Biotech in general, and stocks like Circio rarely go straight up without fluctuations along the way. And there will probably be more red days, where people secure profits, become uncertain, "sell the news", who trade the stock. That is completely normal. But what makes Circio exciting now is that the company suddenly starts delivering on several fronts simultaneously: - strong data - great international attention - patent applications - several collaborations, including research collaboration with AaviGen. - increasing interest around circVec It is precisely such periods that often build the foundation for further upside! The market still seems to be trying to understand how big circVec can actually become. I'm holding on 🚂 (PS: Not financial advice. Do your own research and make your own choices.)
- 5 t sitten5 t sittenDe-Risking Circio: 8 Biological Proofs That circVec Solves the "Mouse-to-Human" Gap In biotech, the biggest risk to our capital is the notorious "Mouse-to-Human" gap. Over 80% of traditional drugs fail in Phase 1/2 clinical trials because human biology rejects what worked perfectly in a lab rat. Circio’s proprietary circular RNA platform, circVec, fundamentally changes this risk profile. Ahead of this Friday’s (May 29) highly anticipated PhD defense at Karolinska Institutet (KI),which documents the precise cellular mechanisms of circular RNA-here are 8 biologically backed reasons why preclinical results for circVec are highly predictive of human clinical success: 1. Universal Biology & "Plug-and-Play" Production The Science: The cellular machinery that processes the circVec vector (ribosomes and spliceosomes) is universal across mammals. The Risk: RNA circularization and ribosome binding efficiency can theoretically vary between mouse and human cells. The Proof (Risk Mitigated): The KI research tested directly on human primary cells, confirming that human cellular machinery perfectly translates circular RNA structures. Furthermore, Circio has continually optimized novel genetic elements (such as those in circVec Gen 4.0) that dramatically improve intracellular circularization efficiency, ensuring maximum, predictable protein output regardless of the host species. 2. Bypassing the "Protein Pocket" Problem The Science: circVec delivers a genetic "software update" to manufacture the human protein directly inside the cell, completely bypassing the structural differences between mouse and human cell receptors that cause chemical drugs to fail. The Risk: Lab mice usually have temporary, "induced" conditions that don't mimic decades of complex human disease progression. The Proof (Risk Mitigated): The KI thesis validated the circRNA mechanism directly on tissues taken from actual patients with chronic, long-standing diabetic ulcers. This proves the technology functions optimally even in a degraded, real-world human disease environment. 3. Extreme and Predictable Stability The Science: The closed, circular structure of circVec-generated RNA evades exonucleases (cellular enzymes that quickly eat standard linear mRNA from the ends). The Risk: Other enzymes (endonucleases) could still chop the RNA from the middle during high cellular stress. The Proof (Risk Mitigated): Circio’s in vivo data demonstrates that circVec achieves significantly extended durability and sustained therapeutic expression in mice compared to linear mRNA. The KI research validates that this superior structural stability holds true in humans, confirming prolonged therapeutic effects even within the highly stressed, oxidative environments of chronic human wounds. 4. Eliminating Unpredictable Liver Toxicity The Science: Unlike chemical drugs, circVec doesn't rely on unpredictable liver enzymes for clearance—a classic point of failure in Phase 1 trials. The Risk: Systemic gene therapies (delivered intravenously) often accumulate in the human liver, causing severe toxicity. The Proof (Risk Mitigated): The KI research proves that localized delivery of circRNA completely avoids systemic blood filtration and liver clearance. This aligns with Circio’s strategic expansion into local and non-viral delivery vectors (such as their partnership with TraffikGene for LNP delivery), allowing the therapy to reach target tissues without risking liver toxicity. 5. Immune "Stealth" and Dramatic Dose Reduction The Science: Standard mRNA often triggers inflammatory alarms because its exposed ends are recognized by the body as viral threats. circVec lacks these ends, allowing it to hide from the innate immune system. The Risk: The viral AAV vector delivering the RNA can still trigger dangerous immune responses if administered in high doses. The Proof (Risk Mitigated): Because circVec generates up to 40-fold higher protein expression than standard mRNA-AAVs, Circio's data confirms that clinical doses can be drastically reduced. Combining significantly lower vector doses with the intracellular "stealth" of circular RNA massively de-risks the threat of trial-killing immune reactions. 6. Exploitation of Universal Repair Cells The Science: Connective tissue cells (fibroblasts) operate identically across all mammals. The Risk: Mice heal wounds by contracting a skin muscle; humans must slowly rebuild tissue from scratch. The Proof (Risk Mitigated): KI researchers used "splinted" models that physically locked the mouse's anatomy, forcing them to heal exactly like humans. The results proved that the fundamental mechanism of circular RNA successfully drives true, human-style tissue regeneration.·5 t sittenI see that Geara defended a PhD in April 2026 but what happens on May 29??? AI???·4 t sittenJennifer Geara defends her doctoral degree this Friday, May 29, and not in April.
- ·7 t sitten...even more attention on LinkedIn, https://www.linkedin.com/posts/pharmanews-biotech-genetherapy-share-7465465764813328385-cq-e/?utm_source=share&utm_medium=member_ios&rcm=ACoAABfsrdgBOH7SNLgjuj2ThRvG2-zvaDmJLOEhttps://www.linkedin.com/posts/martin-busch-186197185_genetherapy-aav-circularrna-share-7465475593606905856-4FZO/?utm_source=share&utm_medium=member_ios&rcm=ACoAABfsrdgBOH7SNLgjuj2ThRvG2-zvaDmJLOE·7 t sitten · MuokattuJust here in the small pond around Oslo S and in West Oslo, they still haven't understood what the company is about to create.🔥 Neither FA, DN nor E24 manage to grasp this. They are going to get a punch in the face when the company is soon bought. It won't be long now. Big Pharma doesn't wait. Now we see Lilly buying pre-clinical every day for 15 mrd. 🔥
- ·7 t sittenThanks — it hits a good middle ground that is often missing in such discussions. You acknowledge both the upside and the risk without ending up in either blind hype or excessive pessimism. Especially the fact that the price remains relatively high after a strong rise is an interesting signal in itself. In many speculative cases, one often sees a full retrace quite quickly when profit-taking begins. That the market still prices Circio around these levels could indicate that more people are actually trying to assess the technology more seriously now. At the same time, you are clear about the most important things: * no one knows the outcome, * biotech is extremely binary, * and the risk is still high. This makes the text more credible than many posts that portray early-stage biotech as almost "guaranteed success".
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 000 | - | - | ||
| 6 000 | - | - | ||
| 1 000 | - | - | ||
| 2 000 | - | - | ||
| 1 284 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt